Skip to content

Evaluation of different treatment thresholds in a clinical pathway for children with acute asthma

Evaluation of different treatment thresholds in a clinical pathway for children with acute asthma - Clinical pathway for acute asthma in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON50952
Enrollment
130
Registered
2021-08-24
Start date
2022-01-18
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute asthma asthma exacerbation

Interventions

The intervention comprises adjusted treatment thresholds for patients with acute asthma who need supplemental oxygen. If randomised to the standard care nurse-driven pathway the treatment threshold

Sponsors

Martini Ziekenhuis
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: -children 2-18 years of age admitted for acute asthma -treatment for acute asthma according to current dutch guideline -supplemental oxygen use, low flow or high flow

Exclusion criteria

Exclusion criteria: -severe acute asthma for which intravenous albuterol is indicated -unstable heart disease -cystic fbrosis or other chronich or congenital lung disease -any neurological disease -any muscular disease -developmental delay

Design outcomes

Primary

MeasureTime frame
Primary outcome is the difference in admission time for children with acute asthma who are treated according to the current nurse-driven pathway or the new pathway with adjusted treatment thresholds for patients who need supplemental oxygen.

Secondary

MeasureTime frame
Secondary outcomes are -number of bronchodilator adminstrations per patient, -the number of deviations from the pathway; administration of bronchodilators when not indicated or when bronchodilators were indicated but not administered. -number or assessments by attending physician -number of patients excluded because they needed treatment with intravenous albuterol -number of re-admission within one week -association between heart rate and the total CAS en individual items of CAS -difference between groups in administration of intravenous magensiumsulphate -difference between groups in transfer to pediatric intensive care unit

Countries

Netherlands

Contacts

Public ContactA.W.A. Kamps

Martini Ziekenhuis

a.kamps@mzh.nl0505247088

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)